SIGA Reports Financial Results for Three and Six Months Ended June 30, 2026
SIGA TECHNOLOGIES INC (SIGA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SIGA Reports Financial Results for Three and Six Months Ended June 30, 2026 • $37 Million of TPOXX Sales Generated in the Second Quarter • Corporate Update Conference Call Today at 4:30 PM ET NEW YORK, August 6, 2026 (GLOBENEWSWIRE) -- SIGA Technologies, Inc. (SIGA)
How this was made
The 30-second read
Why it matters
The disclosure centers on TPOXX sales/deliveries and the statement that Q2 deliveries completed the last procurement order under the 19C contract, which can affect expectations for near-term revenue run-rate and the need for new U.S. and international procurement.
Market read
This is a company-specific earnings-style update with concrete TPOXX delivery numbers and a key contract milestone (19C order completion), alongside YoY declines in product sales and total revenues.
What to watch
Traders may be underweighting the mix shift between IV and oral formulations and the role of R&D revenues in total revenue trends, since operating income margin changes are attributed to product mix.
Background
SIGA filed an SEC Form 8-K with Exhibit 99.1 reporting financial results for the three and six months ended June 30, 2026, plus a corporate update call.
Ticker impact
SIGA reported Q2 and 6M ended June 30, 2026 results, including $37 million of TPOXX sales and completion of the last 19C procurement order.
Near-term volatility possible as traders reprice the durability of TPOXX demand after 19C order completion and the YoY revenue decline.
The filing provides concrete quarterly delivery figures ($37M total; $24M IV to U.S. stockpile; $13M oral internationally) and shows product sales and total revenues down versus 2025, but it does not provide new guidance or a new contract award.
Market effects
Biodefense/pharma counters may see read-across on government stockpile procurement cadence and international commercialization progress for smallpox countermeasures.
U.S. stockpile delivery completion may shift attention to U.S. BARDA procurement timing and Europe/Asia commercialization execution.
International TPOXX deliveries highlight cross-region demand, but the article does not quantify new global contract wins.
Counterpoint
The 19C procurement order completion could be a temporary step-down, while the company’s multi-formulation, multi-region delivery model may still support future contract replenishment.
Key entities
- public_companySIGA Technologies, Inc.
Commercial-stage pharmaceutical company reporting Q2 and 6M 2026 results and TPOXX delivery activity.
- productTPOXX
SIGA’s smallpox countermeasure referenced in delivery and sales figures.
- government_contract19C contract
U.S. procurement contract under which the last procurement order was completed via Q2 deliveries.
- government_agencyBARDA
U.S. Biomedical Advanced Research and Development Authority referenced in forward-looking risk language.
